Latest Health News
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and…
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following…
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe…
Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
June 13, 2026 16:00 ET | Source: Ascendis Pharma Multi-organ system and…
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful…
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026 07:30 ET | Source: Intellia Therapeutics, Inc. Data from…
New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and…
KFSH Highlights the Strategic Value of Tertiary Care AI Datasets in Advancing Precision Medicine and Clinical Innovation
RIYADH, Saudi Arabia, June 12, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist…
